OncoPep Raises $6.9 Million Series B Financing to Advance Novel Cancer Vaccines and Expands Phase 1/2a Clinical Trial

Funding to support expanded clinical development of PVX-410 in combination with lenalidomide in patients with smoldering multiple myeloma Financing includes equity investment from The Leukemia & Lymphoma Society August 28, 2014 OncoPep, Inc., today announced the closing of $6.9 million in Series B financing from new and existing investors. The financing included participation from angel groups, family foundations and individuals, …